
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions surrounding GSK (Gsk Plc) over the past week reflect a mix of sentiment regarding its stock performance and future potential. Key developments noted include promising phase 2 data from ViiV, the company’s HIV drug division, which has bolstered investor optimism about GSK's growth trajectory, particularly as discussions around potential manufacturing relocations persist in the industry. Some investors expressed confidence in the stock's capability to reach £18 to £20 in the long term, indicating a belief in recovery and growth despite historical underperformance, as evidenced by quotes like, “I was scoffed at... when the price was £13.59 for suggesting an upturn was due.”
Financial discussion highlighted the mixed perceptions of GSK's dividend yield and its classification as a defensive stock. While some investors criticized the stock’s capital performance over time, one commenter noted that GSK’s yield has improved to 4.14%, leading to significant discussions about the stock being a defensive play amid market turbulence. Investor sentiment appears cautiously optimistic, with quotes reflecting varied experiences: “For me, that performance has been pretty poor over the time held,” contrasts with, “I like this...20% increase in 2 months.” Overall, the discussions illustrate a complex interplay between historical performance and future potential, with a noted focus on ViiV’s advancements contributing positively to outlook.
Show more
GSK plc has made significant advancements in recent corporate activities, particularly concerning its share buyback program. This week, the company announced the acquisition of 755,000 ordinary shares on March 13, 2025, as part of its previously announced buyback initiative. Over the course of this buyback program initiated on February 24, GSK has purchased a total of approximately 9.77 million shares, with the current treasury holdings reaching about 178.84 million shares after these transactions. The shares were acquired through Citigroup Global Markets, with varying prices reflecting the market conditions.
Additionally, GSK's Chief Executive Officer, Emma Walmsley, engaged in a personal transaction involving the acquisition of ordinary shares under GSK's Share Reward Plan. This adds a layer of commitment among top executives towards the company's performance and future direction. Such developments in shareholding and buyback activities signal GSK's strategic focus on optimizing shareholder value while reinforcing the leadership's alignment with the company’s long-term growth objectives.
Show more
Goes to show that sentiment is hard to change. |
Hate to go against the market but just couldn't resist at this level - I'm in |
On a positive side |
GSK update eases investors’ fears as focus turns to vaccines |
I have just now topped up.Buy and hold.Good news and glad I waited until this afternoon on the dip. Good to see major Good news with gsk.Hopefully this will set them free to move north |
Senior executives at GlaxoSmithKline, including the CEO and CFO, have acquired ordinary shares as part of the company's Share Reward Plan. The transactions, which took place on the London Stock Exchange, involved acquisitions at a price of £14.5185 per share. |
Exited have we trader? |
Dive dive dive |
Not much chance of that. £16-£17 tops if the market behaves itself. I’d be quite happy with that. |
Always quick to dive and slow to go up, sane for virtually all shares. Barring any more unforeseen catastrophes (never a given with GSK) we should see £19-20 within 6 months. |
Some peoples cup is half full even with a hole in the bottom. Odd. |
abdulla - it seems that your cup is always half empty when for others, theirs is half full ;o) |
Nearly 40p down from the HIGH of today |
Yep - we need to get the budget out of the way. |
Look at liontrust. Money is being pulled from the UK daily |
Well I guess that's the end of the litigation Can you offset the litigation costs against your tax liability? |
Yes, should be a lot higher. I suspect a lot of short term traders may take profit but moving forward this is only going in one direction now the shadow of litigation has been removed. |
Why a "gamble on court cases"? (The litigation is virtually over and the price depression was a direct result of the Zantac debacle). The pipeline is strong and the time is long overdue to return to fundamentals. Target: 2000p. |
Feels more like a gamble on court cases rather than an investment in drugs. I think this has a long way to go to get it back to a drugs valuation. |
I think its a disgrace that we have to stump up such a huge amount as there is no proper evidence whatsoever that Zantac causes cancer. Having said that the settlement itself is pragmatic and is the right thing to do. Its way less than many predicted and it stops GSK having their name and reputation dragged through the mud in a never ended series of courts. |
Great settlement for GSK |
Yes now good value, investors hate uncertainty, now settled, good news. |
Even with today's settlement news and 6% jump in share price (so far), GSK continues to be seriously undervalued and remains an outstanding BUY. |
GSK's investment case has significantly improved following its settlement of liability cases related to its discontinued Zantac drug, Deutsche Bank analysts Emmanuel Papadakis and Niall Alexander say in a note. The resolve is a surprising and positive twist to the investment case as it came sooner than expected and should ease investors concerns that had weighed on the shares, they say. Even with the share boost following the news, the pharma giant still seems undervalued based on its projected earnings for 2025, they add. |
Type | Ordinary Share |
Share ISIN | GB00BN7SWP63 |
Sector | Pharmaceutical Preparations |
Bid Price | 1,512.50 |
Offer Price | 1,513.50 |
Open | 1,499.50 |
Shares Traded | 7,113,718 |
Last Trade | 16:35:23 |
Low - High | 1,495.50 - 1,514.00 |
Turnover | 31.38B |
Profit | 2.58B |
EPS - Basic | 0.6211 |
PE Ratio | 24.37 |
Market Cap | 62.15B |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions